CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis

Shauna N. Vasilatos, Gloria Broadwater, William T. Barry, Joseph C. Baker, Siya Lem, Eric C. Dietze, Gregory R. Bean, Andrew D. Bryson, Patrick G. Pilie, Vanessa Goldenberg, David Skaar, Carolyn Paisie, Alejandro Torres-Hernandez, Tracey L. Grant, Lee G. Wilke, Catherine Ibarra-Drendall, Julie H. Ostrander, Nicholas C. D'Amato, Carola Zalles, Randy JirtleValerie M. Weaver, Victoria L. Seewaldt

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: Only 5% of all breast cancers are the result of BRCA1/2 mutations. Methylation silencing of tumor suppressor genes is well described in sporadic breast cancer; however, its role in familial breast cancer is not known. Methods: CpG island promoter methylation was tested in the initial random periareolar fine-needle aspiration sample from 109 asymptomatic women at high risk for breast cancer. Promoter methylation targets included RARB (M3 and M4), ESR1, INK4a/ARF, BRCA1, PRA, PRB, RASSF1A, HIN-1, and CRBP1. Results: Although the overall frequency of CpG island promoter methylation events increased with age (P < 0.0001), no specific methylation event was associated with age. In contrast, CpG island methylation of RARB M4 (P = 0.051), INK4a/ARF (P = 0.042), HIN-1 (P = 0.044), and PRA (P = 0.032), as well as the overall frequency of methylation events (P = 0.004), was associated with abnormal Masood cytology. The association between promoter methylation and familial breast cancer was tested in 40 unaffected premenopausal women in our cohort who underwent BRCA1/2 mutation testing. Women with BRCA1/2 mutations had a low frequency of CpG island promoter methylation (15 of 15 women had ≤4 methylation events), whereas women without a mutation showed a high frequency of promoter methylation events (24 of 25 women had 5-8 methylation events; P < 0.0001). Of women with a BRCA1/2 mutation, none showed methylation of HIN-1 and only 1 of 15 women showed CpG island methylation of RARB M4, INK4a/ARF, or PRB promoters. Conclusions: This is the first evidence of CpG island methylation of tumor suppressor gene promoters in non-BRCA1/2 familial breast cancer.

Original languageEnglish (US)
Pages (from-to)901-914
Number of pages14
JournalCancer Epidemiology Biomarkers and Prevention
Volume18
Issue number3
DOIs
StatePublished - Mar 1 2009

Fingerprint

CpG Islands
Carcinogens
Methylation
Carcinogenesis
Breast
Mutation
Breast Neoplasms
Tumor Suppressor Genes
Fine Needle Biopsy

Cite this

Vasilatos, S. N., Broadwater, G., Barry, W. T., Baker, J. C., Lem, S., Dietze, E. C., ... Seewaldt, V. L. (2009). CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiology Biomarkers and Prevention, 18(3), 901-914. https://doi.org/10.1158/1055-9965.EPI-08-0875

CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. / Vasilatos, Shauna N.; Broadwater, Gloria; Barry, William T.; Baker, Joseph C.; Lem, Siya; Dietze, Eric C.; Bean, Gregory R.; Bryson, Andrew D.; Pilie, Patrick G.; Goldenberg, Vanessa; Skaar, David; Paisie, Carolyn; Torres-Hernandez, Alejandro; Grant, Tracey L.; Wilke, Lee G.; Ibarra-Drendall, Catherine; Ostrander, Julie H.; D'Amato, Nicholas C.; Zalles, Carola; Jirtle, Randy; Weaver, Valerie M.; Seewaldt, Victoria L.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 18, No. 3, 01.03.2009, p. 901-914.

Research output: Contribution to journalArticle

Vasilatos, SN, Broadwater, G, Barry, WT, Baker, JC, Lem, S, Dietze, EC, Bean, GR, Bryson, AD, Pilie, PG, Goldenberg, V, Skaar, D, Paisie, C, Torres-Hernandez, A, Grant, TL, Wilke, LG, Ibarra-Drendall, C, Ostrander, JH, D'Amato, NC, Zalles, C, Jirtle, R, Weaver, VM & Seewaldt, VL 2009, 'CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis', Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 3, pp. 901-914. https://doi.org/10.1158/1055-9965.EPI-08-0875
Vasilatos, Shauna N. ; Broadwater, Gloria ; Barry, William T. ; Baker, Joseph C. ; Lem, Siya ; Dietze, Eric C. ; Bean, Gregory R. ; Bryson, Andrew D. ; Pilie, Patrick G. ; Goldenberg, Vanessa ; Skaar, David ; Paisie, Carolyn ; Torres-Hernandez, Alejandro ; Grant, Tracey L. ; Wilke, Lee G. ; Ibarra-Drendall, Catherine ; Ostrander, Julie H. ; D'Amato, Nicholas C. ; Zalles, Carola ; Jirtle, Randy ; Weaver, Valerie M. ; Seewaldt, Victoria L. / CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. In: Cancer Epidemiology Biomarkers and Prevention. 2009 ; Vol. 18, No. 3. pp. 901-914.
@article{9234d966e8fc4d2b8540ddb51edf7988,
title = "CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis",
abstract = "Background: Only 5{\%} of all breast cancers are the result of BRCA1/2 mutations. Methylation silencing of tumor suppressor genes is well described in sporadic breast cancer; however, its role in familial breast cancer is not known. Methods: CpG island promoter methylation was tested in the initial random periareolar fine-needle aspiration sample from 109 asymptomatic women at high risk for breast cancer. Promoter methylation targets included RARB (M3 and M4), ESR1, INK4a/ARF, BRCA1, PRA, PRB, RASSF1A, HIN-1, and CRBP1. Results: Although the overall frequency of CpG island promoter methylation events increased with age (P < 0.0001), no specific methylation event was associated with age. In contrast, CpG island methylation of RARB M4 (P = 0.051), INK4a/ARF (P = 0.042), HIN-1 (P = 0.044), and PRA (P = 0.032), as well as the overall frequency of methylation events (P = 0.004), was associated with abnormal Masood cytology. The association between promoter methylation and familial breast cancer was tested in 40 unaffected premenopausal women in our cohort who underwent BRCA1/2 mutation testing. Women with BRCA1/2 mutations had a low frequency of CpG island promoter methylation (15 of 15 women had ≤4 methylation events), whereas women without a mutation showed a high frequency of promoter methylation events (24 of 25 women had 5-8 methylation events; P < 0.0001). Of women with a BRCA1/2 mutation, none showed methylation of HIN-1 and only 1 of 15 women showed CpG island methylation of RARB M4, INK4a/ARF, or PRB promoters. Conclusions: This is the first evidence of CpG island methylation of tumor suppressor gene promoters in non-BRCA1/2 familial breast cancer.",
author = "Vasilatos, {Shauna N.} and Gloria Broadwater and Barry, {William T.} and Baker, {Joseph C.} and Siya Lem and Dietze, {Eric C.} and Bean, {Gregory R.} and Bryson, {Andrew D.} and Pilie, {Patrick G.} and Vanessa Goldenberg and David Skaar and Carolyn Paisie and Alejandro Torres-Hernandez and Grant, {Tracey L.} and Wilke, {Lee G.} and Catherine Ibarra-Drendall and Ostrander, {Julie H.} and D'Amato, {Nicholas C.} and Carola Zalles and Randy Jirtle and Weaver, {Valerie M.} and Seewaldt, {Victoria L.}",
year = "2009",
month = "3",
day = "1",
doi = "10.1158/1055-9965.EPI-08-0875",
language = "English (US)",
volume = "18",
pages = "901--914",
journal = "Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis

AU - Vasilatos, Shauna N.

AU - Broadwater, Gloria

AU - Barry, William T.

AU - Baker, Joseph C.

AU - Lem, Siya

AU - Dietze, Eric C.

AU - Bean, Gregory R.

AU - Bryson, Andrew D.

AU - Pilie, Patrick G.

AU - Goldenberg, Vanessa

AU - Skaar, David

AU - Paisie, Carolyn

AU - Torres-Hernandez, Alejandro

AU - Grant, Tracey L.

AU - Wilke, Lee G.

AU - Ibarra-Drendall, Catherine

AU - Ostrander, Julie H.

AU - D'Amato, Nicholas C.

AU - Zalles, Carola

AU - Jirtle, Randy

AU - Weaver, Valerie M.

AU - Seewaldt, Victoria L.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Background: Only 5% of all breast cancers are the result of BRCA1/2 mutations. Methylation silencing of tumor suppressor genes is well described in sporadic breast cancer; however, its role in familial breast cancer is not known. Methods: CpG island promoter methylation was tested in the initial random periareolar fine-needle aspiration sample from 109 asymptomatic women at high risk for breast cancer. Promoter methylation targets included RARB (M3 and M4), ESR1, INK4a/ARF, BRCA1, PRA, PRB, RASSF1A, HIN-1, and CRBP1. Results: Although the overall frequency of CpG island promoter methylation events increased with age (P < 0.0001), no specific methylation event was associated with age. In contrast, CpG island methylation of RARB M4 (P = 0.051), INK4a/ARF (P = 0.042), HIN-1 (P = 0.044), and PRA (P = 0.032), as well as the overall frequency of methylation events (P = 0.004), was associated with abnormal Masood cytology. The association between promoter methylation and familial breast cancer was tested in 40 unaffected premenopausal women in our cohort who underwent BRCA1/2 mutation testing. Women with BRCA1/2 mutations had a low frequency of CpG island promoter methylation (15 of 15 women had ≤4 methylation events), whereas women without a mutation showed a high frequency of promoter methylation events (24 of 25 women had 5-8 methylation events; P < 0.0001). Of women with a BRCA1/2 mutation, none showed methylation of HIN-1 and only 1 of 15 women showed CpG island methylation of RARB M4, INK4a/ARF, or PRB promoters. Conclusions: This is the first evidence of CpG island methylation of tumor suppressor gene promoters in non-BRCA1/2 familial breast cancer.

AB - Background: Only 5% of all breast cancers are the result of BRCA1/2 mutations. Methylation silencing of tumor suppressor genes is well described in sporadic breast cancer; however, its role in familial breast cancer is not known. Methods: CpG island promoter methylation was tested in the initial random periareolar fine-needle aspiration sample from 109 asymptomatic women at high risk for breast cancer. Promoter methylation targets included RARB (M3 and M4), ESR1, INK4a/ARF, BRCA1, PRA, PRB, RASSF1A, HIN-1, and CRBP1. Results: Although the overall frequency of CpG island promoter methylation events increased with age (P < 0.0001), no specific methylation event was associated with age. In contrast, CpG island methylation of RARB M4 (P = 0.051), INK4a/ARF (P = 0.042), HIN-1 (P = 0.044), and PRA (P = 0.032), as well as the overall frequency of methylation events (P = 0.004), was associated with abnormal Masood cytology. The association between promoter methylation and familial breast cancer was tested in 40 unaffected premenopausal women in our cohort who underwent BRCA1/2 mutation testing. Women with BRCA1/2 mutations had a low frequency of CpG island promoter methylation (15 of 15 women had ≤4 methylation events), whereas women without a mutation showed a high frequency of promoter methylation events (24 of 25 women had 5-8 methylation events; P < 0.0001). Of women with a BRCA1/2 mutation, none showed methylation of HIN-1 and only 1 of 15 women showed CpG island methylation of RARB M4, INK4a/ARF, or PRB promoters. Conclusions: This is the first evidence of CpG island methylation of tumor suppressor gene promoters in non-BRCA1/2 familial breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=64549127819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64549127819&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-08-0875

DO - 10.1158/1055-9965.EPI-08-0875

M3 - Article

C2 - 19258476

AN - SCOPUS:64549127819

VL - 18

SP - 901

EP - 914

JO - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

SN - 1055-9965

IS - 3

ER -